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Background: Outcomes of antibiotic treatment for lung disease caused by nontuberculous mycobacteria (NTM) are
unsatisfactory. The role of adjunctive surgery in the treatment of NTM lung disease is still unclear.
Methods: We conducted a retrospective review of 70 patients who underwent pulmonary resection for NTM lung
disease from March 2007 to February 2013. All patients received recommended antibiotic treatment before and
after the surgery.
Results: A total of 70 patients underwent 74 operations. The median age of the patients was 50 years. Of the 70
patients, 45 (64%) had Mycobacterium avium complex infection (24M. intracellulare and 21M. avium) and 23 (33%)
had M. abscessus complex infection (15M. abscessus and 8M. massiliense). Thirty-eight (54%) patients had the nodular
bronchiectatic form and 28 (40%) had the fibrocavitary form of NTM lung disease. The indications for surgery were a
poor response to drug therapy (n=52), remnant cavitary lesions and severe bronchiectasis (n=14), and hemoptysis
(n=4). Preoperative sputum acid-fast bacilli staining results were positive in 44 (63%) patients, and sputum culture was
positive in 54 (76%). The surgery included lobectomy or lobectomy plus segmentectomy (n=50, 68%), segmentectomy
(n=11, 15%), pneumonectomy or completion pneumonectomy (n=8, 11%), bilobectomy or bilobectomy plus
segmentectomy (n=4, 5%), and wedge resection (n=1, 1%). Postoperative complications occurred in 15 (21%)
patients, including one postoperative death and bronchopleural fistula in 5 patients with the fibrocavitary form of
the disease. A negative sputum culture was achieved and maintained in 57 (81%) patients.
Conclusions: Although adjuvant pulmonary resection is associated with a relatively high complication rate, this
procedure may provide a high level of treatment success for selected patients with NTM lung disease, such as
those with a poor response to antibiotic treatment alone.
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Nontuberculous mycobacteria (NTM) refer generally to
mycobacteria other than Mycobacterium tuberculosis
complex and M. leprae. The prevalence of lung diseases
caused by NTM is increasing worldwide [1,2]. NTM
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Of the various species of NTM, Mycobacterium avium
complex (MAC) such as M. avium and M. intracellulare
and M. abscessus complex such as M. abscessus and M.
massiliense are the most common causes of NTM lung
disease [3,4].
A major therapeutic advance in the treatment of NTM
lung disease was the introduction of the newer macrolides,
clarithromycin and azithromycin, which have substantial
in vitro and clinical activity against MAC and M. abscessus
complex [1,2]. However, the treatment success rates for
patients receiving combination antibiotic treatment forhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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success rates of medical treatment were approximately
40-55% in patients with MAC lung disease [5,6] and
approximately 25-30% in those with M. abscessus lung
disease [7-9]. Therefore, adjuvant resectional surgery
could be considered in patients with intractable NTM
lung disease predominantly localized to one lung and
who can tolerate resectional surgery [10,11].
The increasing prevalence of NTM lung disease has
been paralleled by increasing reports on the role of
surgery since the introduction of the newer macrolides
[12-25], suggesting more frequent use of thoracic sur-
gery in the management of NTM lung disease. However,
a majority of these reports were from limited centers in
the Unites States and Japan, and the criteria for selecting
the patients who may benefit from the operation remain
controversial [10,26,27]. More data on the treatment
outcomes of patients with NTM lung disease undergo-
ing surgical resection in settings of various etiologic or-
ganisms will help determine the optimal role of adjuvant
surgery.
The number of patients with NTM lung disease has
continued to increase in South Korea [28-31]. We previ-
ously reported the treatment outcomes in 23 patients
who underwent pulmonary resections for NTM lung
disease [20]. This study reports our further experience of
adjuvant surgical therapy in 70 patients with NTM lung
disease.Methods
Patients
We retrospectively reviewed the medical records of all
patients who underwent adjunctive pulmonary resec-
tional surgery for NTM lung disease at Samsung Med-
ical Center (a 1,961-bed referral hospital in Seoul,
Korea) between March 2007 and February 2013. During
this period, a total of 70 patients underwent pulmonary
resection for NTM lung disease. All patients met the
diagnostic criteria for NTM lung disease [1].
NTM species were identified using polymerase chain
reaction (PCR)-restriction fragment length polymorph-
ism analysis or a PCR-reverse blot hybridization assay of
the mycobacterial rpoB gene [32-34]. We classified chest
radiography and high-resolution computed tomography
(HRCT) scan findings as showing either fibrocavitary
disease or nodular bronchiectatic disease. When the
disease did not belong to either the fibrocavitary form or
the nodular bronchiectatic form, it was deemed unclassi-
fiable [35-38].
This study was approved by the Institutional Review
Board of Samsung Medical Center to review and publish
information obtained from patient records (IRB No.
2014-07-171). Informed consent was waived for the useof patient medical data and patient information was
anonymized and de-identified prior to analysis.
Preoperative antibiotic treatment
All patients with NTM lung disease received the stand-
ard combination antibiotic therapy according to the
American Thoracic Society guidelines [1]. For treating
MAC lung disease, patients received antibiotic therapy
consisting of oral macrolide (clarithromycin or azithro-
mycin), ethambutol, and rifampin. When necessary,
streptomycin injection was added to the regimen in
patients with severe MAC lung disease [35,39,40].
Patients with M. abscessus lung disease were treated
with oral macrolide (clarithromycin or azithromycin)
and/or oral fluoroquinolone (ciprofloxacin or moxifloxa-
cin) in combination with parenteral antibiotics, includ-
ing amikacin and cefoxitin (or imipenem), for the first
4 weeks of hospitalization [41]. For patients with M.
massiliense lung disease, the same antibiotic regimens
were used between March 2007 and September 2010.
After October 2010, the initial duration of parenteral
antibiotic therapy was reduced from 4 weeks to 2 weeks
in patients with M. massiliense lung disease [42] because
the treatment outcomes of antibiotic therapy were rec-
ognized to be superior in patients with M. massiliense
lung disease than in those with M. abscessus lung disease
[8,43,44]. The same oral regimens were used after
discharge in patients with M. abscessus complex lung
disease.
Surgical treatment
Patients were selected for surgery based on consensus
by medical and surgical specialists. In general, indica-
tions for pulmonary resection included (a) a poor re-
sponse to medical therapy, (b) remnant cavitary lesions
and/or severe focal bronchiectasis, and (c) development
of complications such as massive hemoptysis [20]. Al-
though there is no standard definition for NTM lung
disease treatment failure, experts recommend that treat-
ment failure be defined as failure to convert sputum to
culture negative after at least 6 months of recommended
therapy [10,22]. Therefore, we carefully selected patients
who would benefit from resectional surgery, usually after
at least 6 months of antibiotic treatment if these patients
had not undergone previous treatment for NTM lung
disease. However, we considered surgery more actively
in some patients even before they completed 6 months
of antibiotic therapy, if the patients had recurrent NTM
lung disease with a history of previous treatment or had
been transferred to our hospital because of persistent
positive culture despite several months of antibiotic
therapy. Surgical candidates had to have sufficient
pulmonary function (≥40% of predictive postoperative
forced expiratory volume in one second (FEV1) [45] to
Table 1 Baseline characteristics of 70 patients
Characteristic No. (%) or
median (IQR)
Age, years 50 (43–58)
Sex, male 28 (40)
Body mass index, kg/m2 20.8 (19.7-22.5)
Non-smoker 51 (73)
Underlying disease
History of pulmonary TB 45 (64)
Previous therapy for NTM lung disease 6 (9)
Receiving antibiotic therapy at the time of transfer 15 (21)
Previous lung resection 4 (6)
Diabetes mellitus 5 (7)
Etiology
Mycobacterium avium complex 45 (64)
M. intracellulare / M. avium 24 / 21
Mycobacterium abscessus complex 23 (33)
M. abscessus / M. massiliense 15 / 8
Mixed infection 2 (3)
Type of disease




Positive AFB stain 44 (63)
Positive AFB culture 54 (76)
Preoperative pulmonary function test
FVC (L) 2.82 (2.40-3.37)
FVC, % predicted 80 (70–95)
FEV1 (L) 2.19 (1.73-2.62)
FEV1, % predicted 81 (63–92)
The data are presented as medians and interquartile ranges or as numbers (%).
IQR, interquartile range; TB, tuberculosis; AFB, acid-fast bacilli; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity.
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terial burden. For patients with bilateral lesions, the area
with the larger bacterial burden was resected, and the
remaining lesion with the smaller bacterial burden in the
ipsilateral or contralateral lung was controlled with
medical therapy. If treatment was ineffective, additional
surgery was considered.
The standard preoperative work-up included chest
radiography, chest HRCT, pulmonary function tests,
quantitative lung perfusion scan, electrocardiogram,
echocardiography, and bronchoscopy. Surgery was per-
formed under general anesthesia using a double-lumen
endobronchial tube. For patients in whom dense pleural
adhesions were anticipated, such as those with apical
fibrocavitary disease, we performed a posterolateral
thoracotomy. For patients in whom dense pleural adhe-
sions were not anticipated, such as those with middle
lobe and lingular bronchiectatic disease, video-assisted
thoracoscopic surgery was performed [26].
The same oral antibiotic regimens (oral macrolide,
ethambutol, and rifampin for MAC lung disease and oral
macrolide and/or oral fluoroquinolone for M. abscessus
complex lung disease) were maintained after surgical
resection and continued for at least 12 months after
sputum culture conversion, defined as three consecutive
negative sputum cultures.
Statistical analyses
The data are presented as medians and interquartile
ranges (IQR) for continuous variables and as numbers
(percentages) for categorical variables. The data were
compared using the Mann–Whitney U test for continu-
ous variables and Pearson’s χ2 test or Fisher’s exact test
for categorical variables. All statistical analyses were per-
formed using PASW Statistics 20 (SPSS Inc., Chicago, IL).
Results
Baseline characteristics
The patient group included 42 females (60%) and 28
males (40%), with a median age of 50 years (IQR, 43–58
years). The median body mass index was 20.8 kg/m2
(IQR, 19.7-22.5 kg/m2). Fifty-one (73%) patients were
nonsmokers. Six patients had recurrent NTM lung dis-
ease with a history of previous treatment of NTM lung
disease and 15 patients were transferred to our hospital
because of persistent positive culture despite several
months of antibiotic therapy. Four patients had a history
of previous pulmonary resection for pulmonary tubercu-
losis (n=2) or NTM lung disease (n=2).
None of the patients tested positive for human im-
munodeficiency virus. Median preoperative forced vital
capacity was 2.82 L (IQR, 2.40-3.37 L), and forced
expiratory volume in one second was 2.19 L (IQR 1.73-
2.62 L) (Table 1).Of the 70 patients, 45 (64%) had MAC infection (M.
intracellulare in 24 and M. avium in 21), 23 (33%) had
M. abscessus complex infection (M. abscessus in 15 and
M. massiliense in 8), and two (3%) had mixed MAC and
M. abscessus infection. The preoperative sputum smear
and culture results were positive in 44 (63%) and 54
(76%) patients, respectively. Based on the chest radiog-
raphy and HRCT findings, 38 (54%) patients had the
nodular bronchiectatic form and 28 (40%) had the
fibrocavitary form of NTM lung disease (Table 1).
Medical and surgical treatment
The indications for surgery included a poor response to
medical therapy (n=52, 74%), remnant cavitary lesions
and/or severe focal bronchiectasis (n=14, 20%), and
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Standardized combination antibiotic therapy was admin-
istered preoperatively in all patients. The median dur-
ation of preoperative antibiotic therapy was 8.3 months
(IQR, 3.8-14.7 months). In 21 patients who had recur-
rent NTM lung disease or who were transferred to our
hospital because of persistent positive culture despite
long-term antibiotic treatment, the duration of antibiotic
treatment in our hospital was a median of 6.7 months
(IQR 2.6-8.2 months), which was shorter compared with
the 49 patients who did not have a history of previous
NTM lung disease and started antibiotic therapy in our
hospital (median 11.0 months, IQR 4.9-18.2 months,
P=0.018).
Among 45 patients with MAC lung disease, strepto-
mycin injection was added in 21 patients with the
fibrocavitary form and nine patients with nodular
bronchiectatic or unclassifiable form who had cavitary
lesions. However, three patients discontinued strepto-
mycin due to side effects such as skin rash or perioral
tingling sensation. Among 15 patients with the nodular
bronchiectatic or an unclassifiable form who did not
have cavitary lesions, six patients received streptomycin
injection at the discretion of the attending physician.
The 70 patients underwent 74 pulmonary resections
(Table 2). Open thoracotomy, minithoracotomy with
video assistance, and video-assisted thoracoscopic sur-
gery without minithoracotomy were performed in 47
(64%), 1 (1%), and 26 (35%) resections, respectively.
Bronchial stump reinforcement was performed in two
patients (one patient receiving lobectomy plus segmen-
tectomy and one receiving bilobectomy).
Postoperative complications
There were no intraoperative deaths. There was one
postoperative death during hospitalization; a 57-year-old
man with M. intracellulare lung disease died of pneumo-
nia and acute respiratory failure 79 days after undergoingTable 2 Type of lung resection and postoperative complicatio
Type of resection No. (%) of lung resection (n=74) Com
[Right/Left] Afte
Pneumonectomy 5 (7%) [2/3] Post
Completion pneumonectomy 3 (4%) [1/2] Emp
Bilobectomy plus segmentectomy 1 (1%) [1/0] BPF,
Bilobectomy 3 (4%) [3/0] non
Lobectomy plus segmentectomy 8 (11%) [4/4] BPF
Lobectomy 42 (57%) [25/17] BPF
Pne
Segmentectomy 11 (15%) [4/7] Non
Wedge resection 1 (1%) [1/0] Non
BPF, bronchopleural fistula.
*Postoperative bronchopleural fistula, empyema, and wound dehiscence developedright pneumonectomy. Postoperative complications oc-
curred in 15 patients (21%), including one postoperative
death (Table 2). Among four patients who underwent the
second surgery, one patient developed bronchopleural
fistula after the first surgery. Postoperative complica-
tion rates did not differ between patients with pre-
operative positive sputum culture results (19% [13/54])
and those with preoperative negative sputum culture
results (13% [2/16], P=0.322). Postoperative complica-
tion rates were slightly low after video-assisted thoraco-
scopic surgery (15% [4/27]) compared with those after
open thoracotomy (23% [11/47]); however, this was not
a significant difference (P=0.376).
All five patients who developed bronchopleural fistula
had the fibrocavitary form of NTM lung disease (two in
MAC and three in M. abscessus complex). Preoperative
sputum smear and culture were positive in four (80%)
and five (100%) patients, respectively. The type of resec-
tion included bilobectomy plus segmentectomy (n=1),
lobectomy plus segmentectomy (n=2), lobectomy (n=1),
and segmentectomy (n=1).
Among 45 patients with MAC lung disease, the post-
operative complication rate was high (21% [7/33]) in 33
patients who received streptomycin injection compared
with 12 patients who did not receive streptomycin injec-
tion (8% [1/12]); however, this difference was not statisti-
cally significant (P=0.318). Among 23 patients with M.
abscessus complex lung disease, 19 patients received
perioperative parenteral antibiotics such as amikacin and
cefoxitin (or imipenem) for a median of 28 days (IQR
25–33 days). Postoperative complication rates did not
differ between patients who received perioperative par-
enteral antibiotics (26% [5/19]) and those who did not
(25% [1/4], P=0.957).
Treatment outcomes
Postoperative antibiotic therapy was administered to all
patients, with a median treatment time of 12.7 monthsns
plications (n=15)
r right-sided resection After left-sided resection
operative mortality (1) None (0)
yema (1) Vocal cord palsy (1)
empyema, wound dehiscence (1)* None (0)
e (0) None (0)
(1), wound dehiscence (1) BPF (1), empyema (1)
(1), wound dehiscence (1),
umonia (1)
Wound dehiscence (1), Pericarditis (1),
atrial fibrillation (1)
e (0) BPF (1)
e (0) None (0)
in the same patient.
Table 3 Baseline characteristics of 45 patients with MAC






Age, years 50 (43–61) 50 (42–55) 0.241
Sex, male 21 (50) 6 (26) 0.101
Type of disease 0.181
Nodular bronchiectatic 21 (47) 16 (70)
Fibrocavitary 21 (47) 7 (30)
Unclassifiable 3 (7) 0
Preoperative sputum
examinations
Positive AFB stain 26 (58) 17 (74) 0.192
Positive AFB culture 35 (78) 17 (74) 0.722
Indications of surgery 0.812
Poor response to medical
therapy
34 (76) 16 (70)
Remnant destroyed lesions 8 (18) 6 (26)
Massive hemoptysis 3 (7) 1 (4)
Type of resection* 0.292
Pneumonectomy 4 (9) 1 (4)




Bilobectomy 1 (2) 2 (8)
Lobectomy plus
segmentectomy
3 (6) 4 (16)
Lobectomy 26 (55) 15 (60)
Segmentectomy 9 (19) 2 (8)
Wedge resection 1 (2) 0
Surgical approach 0.596
Open thoracotomy 29 (62) 17 (68)
Thoracoscopic approach† 18 (38) 9 (32)
Postoperative complications 0.529
Postoperative mortality 1 (2) 0 1.000
Bronchopleural fistula 2 (4) 3 (13) 0.334
Wound dehiscence 0 3 (13) 0.035
Empyema 1 (2) 2 (9) 0.257
Pneumonia 1 (2) 0 1.000
Vocal cord palsy 1 (2) 0 1.000
Pericarditis 1 (2) 0 1.000
Atrial fibrillation 1 (2) 0 1.000
Sputum culture conversion 39 (87) 16 (70) 0.111
The data are presented as medians and interquartile ranges or as numbers (%).
MAC, Mycobacterium avium complex; TB, tuberculosis; AFB, acid-fast bacilli.
*Forty-five MAC patients underwent 47 operations, and 23 M. abscessus
complex patients underwent 25 operations.
†One patient underwent surgery using the thoracoscopic approach with
minithoracotomy.
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regimens (oral macrolide, ethambutol, and rifampin for
MAC lung disease and oral macrolide and/or oral
fluoroquinolone for M. abscessus complex lung disease)
were used after surgical resection. Of 70 patients, 57
(81%) achieved sputum culture conversion. No relapse
occurred in these patients during a median follow-up
period of 27.3 months (IQR, 19.8 to 36.9 months).
Among 45 patients with MAC lung disease, the
sputum culture conversion rate was low (82% [27/33]) in
the 33 patients who received streptomycin injection
compared with the 12 patients who did not receive
streptomycin injection (100% [12/12]); however, this dif-
ference was not statistically significant (P=0.472). In 23
patients with M. abscessus complex lung disease, sputum
culture conversion rates were not different between pa-
tients who received perioperative parenteral antibiotics
(63% [12/19]) and those who did not (100% [4/4],
P=0.957).
Among the four patients who underwent a second
resectional surgery, three obtained successful sputum
culture conversion after the second resection, while one
patient failed to achieve sputum culture conversion. Late
death occurred in one patient with M. abscessus lung
disease at 53 months after surgery due to pneumonia
and empyema associated with bronchopleural fistula.
Comparisons between patients with MAC lung disease
and those with M. abscessus complex lung disease
We compared preoperative baseline characteristics, type
of surgery, and treatment outcomes between 45 patients
with MAC lung disease and 23 with M. abscessus com-
plex lung disease after exclusion of two patients with
mixed infection. As shown in Table 3, the preoperative
baseline characteristics did not differ between the two
groups. Type of lung resection and the proportion of
patients who underwent surgery using a thoracoscopic
approach were not different between the two groups.
Although the total postoperative complication rates did
not differ between the two groups, development of
wound dehiscence was more frequent in patients with
M. abscessus complex compared with MAC patients
(13% [3/23] vs. 0% [0/45], P=0.035). Although sputum
culture conversion rates were higher in MAC patients
(87% [39/45]) compared with M. abscessus complex pa-
tients (70% [16/23]), this difference was not statistically
significant (P=0.111, Table 3).
Comparisons between patients with nodular
bronchiectatic form and those with fibrocavitary form of
NTM lung disease
We compared preoperative baseline characteristics, type
of surgery, and treatment outcomes for 38 patients with
the nodular bronchiectatic form and 28 with the
Table 4 Baseline characteristics of 38 patients with
nodular bronchiectatic and 28 with fibrocavitary







Age, years 52 (43–60) 51 (44–60) 0.943
Sex, male 9 (24) 17 (61) 0.002
Etiology 0.195
M. avium complex 21 (55) 21 (75)
M. abscessus complex 16 (42) 7 (25)
Mixed infection 1 (3) 0
Preoperative sputum
examinations
Positive AFB stain 20 (53) 20 (71) 0.122
Positive AFB culture 25 (66) 25 (89) 0.028
Indications of surgery 0.254
Poor response to medical
therapy
26 (68) 22 (79)
Remnant destroyed lesions 8 (21) 6 (21)
Massive hemoptysis 4 (11) 0 (0)
Type of resection* 0.465
Pneumonectomy 2 (5) 3 (10)




Bilobectomy 3 (7) 0
Lobectomy plus
segmentectomy
4 (10) 3 (10)
Lobectomy 25 (61) 14 (48)
Segmentectomy 5 (12) 6 (21)
Wedge resection 1 (2) 0
Surgical approach 0.012
Open thoracotomy 22 (54) 24 (83)
Thoracoscopic approach† 19 (46) 5 (17)
Postoperative complications 0.029
Postoperative mortality 0 1 (4) 0.424
Bronchopleural fistula 0 5 (18) 0.011
Wound dehiscence 1 (3) 2 (7) 0.570
Empyema 2 (5) 1 (4) 1.000
Pneumonia 0 1 (4) 0.424
Vocal cord palsy 0 1 (4) 0.424
Pericarditis 0 0 1.000
Atrial fibrillation 1 (3) 0 1.000
Sputum culture conversion 30 (79) 23 (82) 0.747
The data are presented as medians and interquartile ranges or as numbers (%).
TB, tuberculosis; AFB, acid-fast bacilli.
*Thirty-eight patients with the nodular bronchiectatic form underwent 41
operations, and 28 patients with the fibrocavitary form underwent 29 operations.
†One patient underwent surgery using a thoracoscopic approach with
minithoracotomy.
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of four patients with unclassifiable forms. Patients with
the nodular bronchiectatic form were more likely to be
female (76% [29/38] vs. 39% [11/28], P=0.002) and non-
smokers (84% [32/38] vs. 61% [17/28], P=0.031), and
also had lower pre-operative sputum positive culture
rates (66% [25/38] vs. 89% [25/28], P=0.028) compared
with patients with the fibrocavitary form of NTM lung
disease (Table 4).
The proportion of thoracoscopic surgery was signifi-
cantly higher in patients with the nodular bronchiectatic
form compared to those with the fibrocavitary form
of NTM lung disease (46% [19/41] vs. 17% [5/29],
P=0.012), although type of lung resection did not differ
between the two groups (Table 4). Among postoperative
complications, bronchopleural fistula developed more
frequently in patients with fibrocavitary lung disease
compared to those with the nodular bronchiectatic form
of NTM lung disease (18% [5/28] vs. 0%, P=0.011). How-
ever, sputum culture conversion rates were not different
between the two groups (Table 4).
Discussion
This study evaluated the treatment outcomes in 70 pa-
tients who underwent adjunctive pulmonary resections
for NTM lung disease. The most common indication for
surgery was a poor response to antibiotic therapy. Suc-
cessful treatment outcomes were achieved in more than
80% of patients in our study, although the postoperative
complication rate was relatively high. The present study
is the second-largest case series to evaluate the role of
adjunctive resectional surgery for NTM lung disease
after reports by a group from Denver in the United
States [21,23,24]. Although postoperative outcomes and
complications vary by type of surgery and severity of
disease, our study results are in agreement with many of
the studies published in the past 20 years (Table 5).
NTM lung disease has become a significant health
problem. However, NTM lung disease remains difficult
to treat with medication alone, although the introduc-
tion of newer macrolides has improved the outcome of
its medical treatment [1,2]. Therefore, pulmonary resec-
tion surgery has been advocated for selected patients
who have localized disease and are able to tolerate resec-
tion to remove gross lesions that contain large numbers
of bacilli [10,11].
Regarding the treatment of NTM lung disease, the
American Thoracic Society guidelines recommend that
the initial therapy for patients with MAC lung disease
consist of a minimum three-drug regimen of oral macro-
lide, ethambutol, and rifampin [1]. In addition, intermit-
tent streptomycin or amikacin injection for the first 2 to
3 months of therapy is recommended to treat extensive
disease [1]. Nevertheless, the success rates of these
Table 5 Treatment outcomes of resectional surgery for NTM lung disease in previous reports published between 1994
and 2014











Pomerantz, 1996 [12] 1983-1996 13 (15) MAC (12) 100 8 0/8
Ono, 1997 [13] 1991-1996 8 (8) MAC (8) 100 13 0/0
Shiraishi, 1998 [14] 1979-1996 33 (33) MAC (33) 94 6 0/15
Nelson, 1998 [15] 1989-1997 28 (28) MAC (28) 79 4 7/29
Shiraishi, 2002 [16] 1993-2001 21 (21) MAC (21) 100 10 0/29
Shiraishi, 2004 [17]* 1983-2002 11 (11) MAC (10), MABC (1) 100 9 18/36
Sherwood, 2005 [18] † 1994-2003 26 (26) MAC (15), MABC (1) 82 0 23/46
Watanabe, 2006 [19] 1990-2005 22 (25) MAC (22) 100 5 0/5
Koh, 2008 [20] 2002-2006 23 (23) MAC (10), MABC (12) 91 0 4/35
Mitchell, 2008 [21] 1983-2006 236 (265) MAC (189), MABC (32) NA NA 3/12
van Ingen, 2010 [22] 2000-2009 8 (8) MAC (7) 88 0 13/50
Yu, 2011 [23] 2004-2009 134 (172) MAC (118), MABC (14) 84 7 0/7
Jarand, 2011 [7] 2001-2008 24 (29) MABC (24) 57 NA 17/25
Mitchell, 2012 [24] 2004-2010 171 (212) MAC (147), MABC (36) NA NA 0/9
Shiraishi, 2013 [25] 2007-2011 60 (65) MAC (55), MABC (3) 100 3 0/12
This study 2007-2013 70 (74) MAC (45), MABC (23) 81 0 1/20
NTM, nontuberculous mycobacteria; MAC, Mycobacterium avium complex; MABC, Mycobacterium abscessus-massiliense complex; NA, not available.
*All patients underwent pneumonectomy.
†All patients underwent completion pneumonectomy.
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relapse rate in patients with sputum conversion at the
completion of medical treatment is high [46].
For the treatment of M. abscessus complex lung dis-
ease, combined intravenous antibiotic therapy including
amikacin and cefoxitin (or imipenem) in addition to the
oral antibiotics was recommended [1]. However, the
antibiotic treatment of lung disease caused by M. abscessus
is usually unsuccessful [7-9]. Therefore, surgery is typically
recommended for patients with localized lung disease who
can withstand lung resection after an initial period on
antimicrobials to reduce the microbial burden [1].
Therefore, the patients whose disease was mainly
localized to one lung and who could tolerate pulmonary
resection were considered for surgery [10,11]. In this
study, we were able to assess the surgical outcomes of
70 patients with NTM lung disease. A majority of our
patients (76%) had preoperative culture-positive sputum
for NTM despite treatment with long-term antibiotic
therapy. However, postoperative negative sputum culture
conversion was achieved and maintained in 81% of
patients and no relapse occurred in these patients during
the follow-up period. These results indicate that pul-
monary resection can play an important role in achiev-
ing a better outcome in selected patients, especially
those in whom medical therapy had failed or who have a
remnant lesion with a high possibility of relapse.The optimal duration of antibiotic therapy before sur-
gery remains controversial [14,26,27]. In the present
study, the median duration of preoperative antibiotics
was 8.3 months. Patients are expected to show clinical
improvement within 3–6 months and for the sputum to
convert to negative within 12 months on antibiotic
treatment regimens [1]. Patients are considered to be
treatment failures if they have not had a response
(microbiologic, clinical or radiographic) after 6 months
of appropriate therapy or have not achieved sputum
conversion to culture-negative after 12 months of appro-
priate therapy [1,10]. Therefore, failure to respond in
these time periods should prompt investigation of the
potential role of surgery.
The optimal duration of antibiotic therapy after surgery
also remains unclear [14,26,27]. The median duration of
postoperative antibiotic therapy was 12.7 months in pa-
tients with successful negative sputum culture conversion
in our study. The guidelines stated that patients with
NTM lung disease should be treated until achieving a
negative sputum culture on therapy for 12 months [1].
This requirement means that postoperative antibiotic
therapy for 12 months would be appropriate if sputum
conversion is achieved after surgery.
Despite the favorable treatment outcomes, postopera-
tive complications were relatively common (21%) with
NTM lung disease in our study. This rate was similar to
Kang et al. BMC Infectious Diseases  (2015) 15:76 Page 8 of 9those of previous studies that reported a high incidence
of postoperative morbidity (Table 5). Among various
postoperative complications, this study found that
wound dehiscence occurred more frequently in patients
with M. abscessus complex lung disease compared to
those with MAC lung disease. This difference may be
related to the fact that M. abscessus complex is naturally
resistant to more antibiotics in clinical use [9,47].
Bronchopleural fistula developed in five patients in our
study population; all of these patients had the fibrocavitary
form of NTM lung disease with severe pleural adhesions
and did not receive bronchial stump reinforcement. We
did not apply bronchial stump reinforcement routinely in
the study period, particularly in the early phase or in cases
with healthy-looking bronchus. The goal of case-by-case
application of bronchial stump reinforcement was to avoid
extra surgical procedures and reduce operation time. For
minimally invasive procedures such as video-assisted thor-
acoscopic surgery, the avoidance of unnecessary proce-
dures is thought to be important. We had quite good
surgical outcomes in a previous study of multidrug resist-
ant and extensively drug-resistant tuberculosis patients
[48]. In that study, there were no cases of bronchopleural
fistula, although only 12 of 72 patients (17%) received
bronchial stump reinforcement [48]. Considering the rela-
tively frequent development of bronchopleural fistula in
NTM patients, however, the present study suggested that
application of bronchial stump reinforcement should be
considered carefully in patients who received resectional
surgery for the fibrocavitary form of NTM lung disease.
Regarding potentially severe postoperative complications,
especially in patients with M. abscessus complex lung
disease or the fibrocavitary form of NTM lung disease,
surgery should be performed at centers employing
thoracic surgeons who have considerable experience with
this type of surgery [1].
Most of the adjunctive surgical procedures for NTM
lung disease included lobectomy or pneumonectomy
other than minimal pulmonary resection. In the current
study, we performed 11 segmentectomies (15%) and one
wedge resection (1%) for patients who had limited le-
sions in each segment of a lobe or marginal pulmonary
function because of underlying pulmonary disease. In
addition, 36% of resections were performed using video-
assisted thoracoscopic surgery. Video-assisted thoraco-
scopic surgery has been more widely used in patients with
NTM lung disease, especially the nodular bronchiectatic
form, in recent years [23,24]. Minimal pulmonary resec-
tion and minimally invasive approaches should be consid-
ered for the preservation of lung parenchyma and lung
function in selected patients who have a small and local-
ized lesion below the segmental level of the lung.
As with all research, the present study is not without
limitations. First, this retrospective study was conductedat a single referral center. Furthermore, the surgical pa-
tients were highly selected, and this selection could bias
the beneficial outcome. Second, the duration of postop-
erative follow-up was relatively short, and this study did
not assess the long-term outcomes, such as relapse rate
after treatment completion. Long-term follow-up is
needed to assess the true efficacy of adjunctive resection
because relapse and reinfection may occur years after
the completion of therapy.
Conclusion
In conclusion, despite its relatively high surgical compli-
cation rate, NTM lung disease in patients with localized
disease and who can tolerate resectional surgery might
be considered for surgery if they have had a poor
response to drug therapy or if they develop significant
disease-related complications such as hemoptysis. Clini-
cians should carefully select those patients with NTM
lung disease who can benefit from adjunctive resectional
surgery.
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